15 June 2023
BerGenBio ASA – Mandatory notification of trade, allocations to primary insiders and close associates in the Rights Issue
Bergen 15 June 2023: Reference is made to previous stock exchange announcements published by BerGenBio ASA (the “Company”), regarding the partially underwritten rights issue of between 1,687,500,000 and 2,500,000,000 new shares in the Company (the “Offer Shares”) at a subscription price of NOK 0.10 per Offer Share (the “Rights Issue”). In addition, the subscribers in the Rights Issue will be allocated one warrant for every two Offer Shares allocated to them and paid by them in the Rights Issue (the “Warrants”). Reference is further made to the mandatory notifications of trade on 7 June, 8 June and 13 June 2023. Following the allocation of Offer Shares and Warrants on 14 June 2023, the following Offer Shares and Warrants have been allocated to primary insiders and their close associates:
Nigel McCracken, CSO of the Company, subscribed for 550,000 Offer Shares in the Rights Issue. McCracken was allocated 285,108 Offer Shares at a price of NOK 0.10 per share and 142 554 Warrants. Following delivery of the Offer Shares, McCracken’s total ownership in the Company amounts to 285,108 shares.
James Barnes, COO of the Company, subscribed for 500,000 Offer Shares in the Rights Issue. Barnes was allocated 259,190 Offer Shares at a price of NOK 0.10 per share and 129,595 Warrants. Following delivery of the Offer Shares, Barnes’s total ownership in the Company amounts to 259,190 shares.
Martin Olin, CEO of the Company, subscribed for 2,000,000 Offer Shares in the Rights Issue. Olin was allocated 2,000,000 Offer Shares at a price of NOK 0.10 per share and 1,000,000 Warrants. Following delivery of the Offer Shares, Olin’s total ownership in the Company amounts to 2,037,100 shares.
Rune Skeie, CFO of the Company, subscribed for 500,000 Offer Shares in the Rights Issue. Skeie was allocated 259,190 Offer Shares at a price of NOK 0.10 per share and 129,595 Warrants. Following delivery of the Offer Shares, Skeie’s total ownership in the Company amounts to 259,190 shares.
Anders Tullgren, Chairman of the Board of the Company, subscribed for 1,409,820 Offer Shares in the Rights Issue. Tullgren was allocated 1,409,820 Offer Shares at a price of NOK 0.10 per share and 704,910 Warrants. Following delivery of the Offer Shares, Tullgren’s total ownership in the Company amounts to 1,459,820 shares.
Svev AS, a company closely associated with and 100% owned by Sveinung Hole, Board member of the Company, subscribed for 2,000,000 Offer Shares in the Rights Issue. Svev AS was allocated 2,000,000 Offer Shares at a price of NOK 0.10 per share and 1,000,000 Warrants. Following delivery of the Offer Shares, Svev’s total ownership in the Company amounts to 2,000,000 shares.
Sally Bennett, Board member of the Company, subscribed for 607,320 Offer Shares in the Rights Issue. Bennett was allocated 314,826 Shares at a price of NOK 0.10 per share and 157,413 Warrants. Following delivery of the Offer Shares, Bennett’s total ownership in the Company amounts to 314,826 shares.
Debra Barker, Board member of the Company, subscribed for 600,000 Offer Shares in the Rights Issue. Barker was allocated 311,027 Shares at a price of NOK 0.10 per share and 155,513 Warrants. Following delivery of the Offer Shares, Barker’s total ownership in the Company amounts to 311,027 shares.
Sarsia Develoment AS, a company closely associated with Sveinung Hole, Board member of the Company, subscribed for 33,500,000 Offer Shares in the Rights Issue. Sarsia Develoment AS was allocated 33,500,000 Offer Shares at a price of NOK 0.10 per share and 16,750,000 Warrants. Following delivery of the Offer Shares, Sarsia Developmen’s total ownership in the Company amounts to 33,675,000 shares.
Sarsia Seed AS, a company closely associated with Sveinung Hole, Board member of the Company, subscribed for 8,100,000 Offer Shares in the Rights Issue. Sarsia Seed AS was allocated 8,100,000 Offer Shares at a price of NOK 0.10 per share and 4,050,000 Warrants. Following delivery of the Offer Shares, Sarsia Seed’s total ownership in the Company amounts to 8,100,000 shares.
Please see further details about the transactions in the attached forms.
This information is subject to the disclosure requirements pursuant to article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin® stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent’s product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).
